Matthew M. Weiss

1.6k total citations
22 papers, 676 citations indexed

About

Matthew M. Weiss is a scholar working on Organic Chemistry, Molecular Biology and Oncology. According to data from OpenAlex, Matthew M. Weiss has authored 22 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Organic Chemistry, 10 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Matthew M. Weiss's work include Asymmetric Synthesis and Catalysis (5 papers), Protein Degradation and Inhibitors (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Matthew M. Weiss is often cited by papers focused on Asymmetric Synthesis and Catalysis (5 papers), Protein Degradation and Inhibitors (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Matthew M. Weiss collaborates with scholars based in United States, Switzerland and France. Matthew M. Weiss's co-authors include John L. Wood, Makoto Hirata, Sarah E. Reisman, Joseph M. Ready, Kazuhiko Tamaki, Timo V. Ovaska, Keiko Hatanaka, Martin Oestreich, Lance A. Pfeifer and Amy B. Dounay and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Cancer Research.

In The Last Decade

Matthew M. Weiss

21 papers receiving 671 citations

Peers

Matthew M. Weiss

OC

MB

PHARM

IC

Tim Luker United Kingdom

David J. St. Jean United States

Klaas Schildknegt United States

Rhona J. Cox Sweden

Kenneth C. Cassidy United States

Andrea M. Zuhl United States

Jason Xiang United States

Ana Belén Garcı́a Spain

Candido Gude United States

Kaushik Mitra United States

Tim Luker United Kingdom

Matthew M. Weiss

606 ×1.1

OC

166 ×1.2

MB

50 ×0.6

PHARM

71 ×1.0

PHARM

78 ×1.1

IC

Citations per year, relative to Matthew M. Weiss Matthew M. Weiss (= 1×) peers Tim Luker

Countries citing papers authored by Matthew M. Weiss

Since Specialization

Citations

This map shows the geographic impact of Matthew M. Weiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew M. Weiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew M. Weiss more than expected).

Fields of papers citing papers by Matthew M. Weiss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew M. Weiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew M. Weiss. The network helps show where Matthew M. Weiss may publish in the future.

Co-authorship network of co-authors of Matthew M. Weiss

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew M. Weiss. A scholar is included among the top collaborators of Matthew M. Weiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew M. Weiss. Matthew M. Weiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Collier, Philip N., Matthew M. Weiss, Dapeng Chen, et al.. (2025). Discovery of Selective and Orally Bioavailable Heterobifunctional Degraders of Cyclin-Dependent Kinase 2. Journal of Medicinal Chemistry. 68(17). 18407–18422. 1 indexed citations

2.

Enerson, Bradley E., Gregg D. Cappon, Yatao Shi, et al.. (2025). Developmental toxicology profile of the IRAK4 degrader KT-474. Toxicological Sciences. 209(2).

3.

Chen, Jesse, Dominico Vigil, Nan Ji, et al.. (2023). Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders. Frontiers in Immunology. 14. 1135373–1135373. 8 indexed citations

4.

Milgram, Benjamin C., R. Foti, Thomas Kornecook, et al.. (2022). Discovery of pyridyl urea sulfonamide inhibitors of NaV1.7. Bioorganic & Medicinal Chemistry Letters. 73. 128892–128892. 1 indexed citations

5.

Klaus, Christine R., Scott Rusin, Kirti Sharma, et al.. (2021). Abstract LB118: Mechanisms underlying synergistic activity in MYD88MTDLBCL of KT-413, a targeted degrader of IRAK4 and IMiD substrate. Cancer Research. 81(13_Supplement). LB118–LB118. 6 indexed citations

6.

Mayo, Michele, Rahul Karnik, Christine R. Klaus, et al.. (2021). KT‐413, A NOVEL IRAKIMID DEGRADER OF IRAK4 AND IMID SUBSTRATES, HAS A DIFFERENTIATED MOA THAT LEADS TO SINGLE‐AGENT AND COMBINATION REGRESSIONS IN MYD88^MT LYMPHOMA MODELS. Hematological Oncology. 39(S2). 8 indexed citations

7.

Boezio, Alessandro A., Kristin L. Andrews, Margaret Y. Chu‐Moyer, et al.. (2018). 1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of NaV1.7 inhibition. Bioorganic & Medicinal Chemistry Letters. 28(11). 2103–2108. 8 indexed citations

8.

Schenkel, Laurie B., Erin F. DiMauro, Hanh Nho Nguyen, et al.. (2017). Discovery of a biarylamide series of potent, state-dependent NaV1.7 inhibitors. Bioorganic & Medicinal Chemistry Letters. 27(16). 3817–3824. 6 indexed citations

9.

Sparling, Brian A., Jessica Able, Howard Bregman, et al.. (2016). Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent Na_V1.7 inhibitors. MedChemComm. 8(4). 744–754. 4 indexed citations

10.

Epstein, O. I., Marian C. Bryan, Alan C. Cheng, et al.. (2014). Lead Optimization and Modulation of hERG Activity in a Series of Aminooxazoline Xanthene β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors. Journal of Medicinal Chemistry. 57(23). 9796–9810. 32 indexed citations

11.

Dineen, Thomas A., Kui Chen, Alan C. Cheng, et al.. (2014). Inhibitors of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1): Identification of (S)-7-(2-Fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′H-spiro[chromeno[2,3-b]pyridine-5,4′-oxazol]-2′-amine (AMG-8718). Journal of Medicinal Chemistry. 57(23). 9811–9831. 49 indexed citations

12.

Wood, Stephen, Paul H. Wen, Jianhua Zhang, et al.. (2012). Establishing the Relationship between In Vitro Potency, Pharmacokinetic, and Pharmacodynamic Parameters in a Series of Orally Available, Hydroxyethylamine-Derived β-Secretase Inhibitors. Journal of Pharmacology and Experimental Therapeutics. 343(2). 460–467. 8 indexed citations

13.

Günaydin, Hakan, Matthew M. Weiss, & Yaxiong Sun. (2012). De Novo Prediction of P-Glycoprotein-Mediated Efflux Liability for Druglike Compounds. ACS Medicinal Chemistry Letters. 4(1). 108–112. 12 indexed citations

14.

Villalobos, Mauricio Navarro, et al.. (2009). Total syntheses of (+)- and (−)-syringolides 3 and of (+)- and (−)-syributins 1, 2 and 3. Tetrahedron. 65(39). 8091–8098. 8 indexed citations

15.

Reisman, Sarah E., Joseph M. Ready, Matthew M. Weiss, et al.. (2008). Evolution of a Synthetic Strategy: Total Synthesis of (±)-Welwitindolinone A Isonitrile. Journal of the American Chemical Society. 130(6). 2087–2100. 140 indexed citations

16.

Ready, Joseph M., Sarah E. Reisman, Makoto Hirata, et al.. (2004). A Mild and Efficient Synthesis of Oxindoles: Progress Towards the Synthesis of Welwitindolinone A Isonitrile. Angewandte Chemie International Edition. 43(10). 1270–1272. 67 indexed citations

17.

Ready, Joseph M., Sarah E. Reisman, Makoto Hirata, et al.. (2004). A Mild and Efficient Synthesis of Oxindoles: Progress Towards the Synthesis of Welwitindolinone A Isonitrile. Angewandte Chemie. 116(10). 1290–1292. 21 indexed citations

18.

Dounay, Amy B., Keiko Hatanaka, Jeremy J. Kodanko, et al.. (2003). Catalytic Asymmetric Synthesis of Quaternary Carbons Bearing Two Aryl Substituents. Enantioselective Synthesis of 3-Alkyl-3-Aryl Oxindoles by Catalytic Asymmetric Intramolecular Heck Reactions. Journal of the American Chemical Society. 125(20). 6261–6271. 176 indexed citations

19.

Bauer, Markus, Petra Maschberger, Lynn Quek, et al.. (2001). Genetic and Pharmacological Analyses of Involvement of Src-family, Syk and Btk Tyrosine Kinases in Platelet Shape Change. Thrombosis and Haemostasis. 85(2). 331–340. 27 indexed citations

20.

Weiss, Matthew M.. (1981). Residence time and accumulation of drugs in the body.. PubMed. 19(2). 82–5. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact